Pemafibrate is a novel, highly selective peroxisome proliferator-activated receptor alpha (PPARα) modulator. It is primarily used to treat hyperlipidemia and also shows therapeutic potential for non-alcoholic fatty liver disease (NAFLD), hypercholesterolemia, and primary biliary cholangitis (PBC).
